Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hemoglobin crosfumaril
- Development stage
- Unknown
- Lead developer
- Baxter Healthcare Corporation
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Hemoglobin crosfumaril is a first-generation, human hemoglobin-based oxygen carrier developed as an artificial blood substitute. It consists of human hemoglobin in which the alpha-subunits are intramolecularly cross-linked using diaspirin fumarate, resulting in increased stability and reduced dissociation compared to native hemoglobin. The drug was designed to function as an oxygen carrier for use in situations such as hypovolemia, shock, and vascular disorders where blood transfusion may not be immediately available or feasible. Its mechanism of action is based on mimicking the oxygen-carrying capacity of red blood cells by circulating modified hemoglobin molecules that can transport and deliver oxygen to tissues[1][2][8]. Development was discontinued after clinical trials due to safety concerns and lack of efficacy benefit over standard care[2].
- Brand names
- HemAssist
- Other names
- hemoglobin crosfumaril (bovine)Haemoglobin crosfumarilHemoglobin A0 (human alpha2 beta2 tetrameric subunit), alpha-chain 99,99'-diamide with (E)-2-butenoic acid
Beyond the preview
Go deeper on hemoglobin crosfumaril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hemoglobin crosfumaril.